	US 11,834,409 B2
	Heterocyclic NMDA antagonists
Shuhei Ikeda, Fujisawa (JP); Makoto Kamata, Fujisawa (JP); Yuya Oguro, Fujisawa (JP); Masataka Murakami, Fujisawa (JP); Minoru Nakamura, Fujisawa (JP); Fumie Yamaguchi, Fujisawa (JP); and Takafumi Yukawa, Fujisawa (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Dec. 22, 2022, as Appl. No. 18/087,233.
Application 18/087,233 is a continuation of application No. 17/755,907, previously published as PCT/IB2020/000962, filed on Nov. 12, 2020.
Claims priority of application No. 2019-206311 (JP), filed on Nov. 14, 2019.
Prior Publication US 2023/0150934 A1, May 18, 2023
Int. Cl. C07D 207/263 (2006.01); A61P 25/18 (2006.01); C07D 401/06 (2006.01)

CPC C07D 207/263 (2013.01) [A61P 25/18 (2018.01); C07D 401/06 (2013.01)]

22 Claims

1. A compound which is (4S,5S)-1-({6-[4-(difluoromethyl)-2-fluorophenoxy]pyridin-3-yl}methyl)-4-hydroxy-5-methylpyrrolidine-2-one or a salt thereof.